Orchid Pharma new antibiotic drug gets EMA approval; stock surges 20%
‘Exblifep’ obtained marketing authorisation from the EMA for the treatment of complex urinary tract infections, pneumonia, and bacteremia caused by ESBL-producing pathogens.
‘Exblifep’ obtained marketing authorisation from the EMA for the treatment of complex urinary tract infections, pneumonia, and bacteremia caused by ESBL-producing pathogens.